Discussion
Regadenoson, is easier to use and associated with better safety and tolerability profiles than non-selective agents such as adenosine and dipyridamole. Vast majority of these side effects are short-lived, benign, and spontaneously terminate. On rare occasions, however, more serious cardiovascular and neurological adverse events may develop, namely symptomatic myocardial ischemia, infarction, high-grade AV block, asystole, and seizures [5] .
Although its affinity at the A1 receptor has been reported to be 10-15-fold weaker, this remains important as these receptors are found at the sinoatrial and atrioventricular node in addition to atrial and ventricular myocytes [6] which is likely the potential source of bradyarrhythmic complications. Also, there has been a theoretical concern of increased and prolonged side effects in patients with chronic kidney disease; however, prior work has demonstrated safety and tolerability in end stage renal disease patients [7, 8] .
Among those totals of 7 reported high degree AV block patients only 2 reportedly had chronic kidney failure. Furthermore, clinical information regarding the 47 cases of complete heart block and 25 cases of sinus arrest reported via the FDA adverse event reporting system (FAERS) is not available [9] hence the real prevalence of regadenoson-induced high-degree AV block remains unknown. It is difficult to predict if a patient with a normal ECG will develop a complete heart block following regadenoson injection. It is important to stress the importance of recognizing potential side effects and treating them immediately [10]. In our case immediate reversal with aminophylline restored sinus rhythm with normal conduction and improvement in symptoms.
We believe the awareness of this potential side effect in nuclear laboratories and readiness of the equipment and drugs in emergency situations is important.
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